


# China life science is off to an impressive start in 2021

In just TWO months, more than \$10 billion in biopharma licensing & partnering deals, financing, IPOs, and a new fund, has been generated in China.



## Licensing & Partnering Deals \$6 billion generated in partnering deals

### TOP THREE DEALS (\$ in M)


<b>\$2,200</b>	Beijing's BeiGene out-licensed ex-China rights for its China-approved anti-PD-1 antibody to Novartis in a \$2.2 billion agreement
<b>\$1,100</b>	Shanghai Junshi Bio out-licensed US-Canada rights for its PD-1 antibody to Coherus Bio in an agreement worth up to \$1.1 billion
<b>\$920</b>	Shanghai's Inmagene in-licensed global rights to four novel pre-clinical immunological molecules from Chi-Med in a \$920 million deal



## Financing \$2.4 billion raised

### TOP THREE DEALS (\$ in M)

<b>\$465</b>	Beijing Yuanxin Technology raised \$465 million in a Series E round to support its online/offline healthcare operations known as Miaoshou Doctor
<b>\$300</b>	BGI Genomics of Shenzhen raised \$300 million in a private placement for its next-gen sequencing services and clinical genetic tests
<b>\$230</b>	Clover Biopharma of Chengdu closed a \$230 million Series C round for its protein-based vaccines and cancer therapies, including a COVID-19 vaccine



## IPOs Over \$1.5 billion raised

### TOP THREE DEALS (\$ in M)

<b>\$407</b>	Beijing InnoCare raised \$407 million in private placements to support its portfolio of 10 candidates for malignant tumors and autoimmune diseases
<b>\$324</b>	Shanghai Microport Cardioflow, a spinout from China device maker Microport, staged a \$324 million Hong Kong IPO for its transcatheter aortic valve implants
<b>\$263</b>	New Horizon Health staged a \$263 million IPO in Hong Kong to support its early cancer screening tests, tripling in initial trading



## One new fund raised \$648 million

CICC Capital announced its RMB biomedical private equity fund, CICC Qide, raised \$648 million as of the second closing.

## If the vibrant and growing China life science market is not part of your strategy, you are missing out!

Join us for ChinaBio® Partnering Forum, May 10–14, 2021, Shanghai and Digital, to accelerate your cross-border strategies by meeting and engaging with 1,000+ international delegates.

**Why wait? The time to expand your reach into this sector is NOW!**

**REGISTER NOW**